SALT LAKE CITY, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, Myriad or the Company), a global leader in molecular diagnostics and precision medicine, today announced the appointment ofPaul J. Diazas President and Chief Executive Officer, effective August 13, 2020. He will also serve on the Companys Board of Directors. Mr. Diaz brings toMyriad Geneticsmore than three decades of executive leadership and business transformation experience in healthcare across a variety of healthcare segments.
Paul is an exceptional leader and executive with extraordinary passion, vision, experience, and operational skills, saidS. Louise Phanstiel, Chair of Myriads Board of Directors. His focus on building high performing teams, and instilling a culture that empowers people to deliver high quality patient care, distinctive customer service and innovation, will be important to supporting Myriads mission and growth. We are excited to have Paul assume the leadership of Myriad Genetics and chart the course to realize the Companys full potential. We look forward to officially introducing Paul during our fourth quarter earnings call. Myriad is dedicated to providing vital information to physicians, patients and their families that enables them to make better decisions about their health and treatment planning. Pauls personal dedication, throughout his career, to patients and their care will be critical in advancing Myriads vision of being a trusted advisor transforming patients lives worldwide with pioneering molecular diagnostics.
I am very excited to join the talented management team and Board of Directors of Myriad Genetics, an organization dedicated to helping patients and physicians identify the risk of developing disease and accurately diagnosing disease and disease progression, commented Paul. Our goal is to empower patients, as consumers, and their physicians and our payer partners with the information and data to help guide their treatment decisions, to improve clinical outcomes and lower healthcare costs.I am equally excited about Myriads potential for innovation and growth.The Company has a tremendous opportunity to transform its business, and strategically position itself for sustainable, profitable growth. We will look to leverage the companys culture of innovation and revitalize our approach to the commercializing of its products and customer service levels.
Mr. Diaz served as the President and Chief Executive Officer and Executive Director and Director of Kindred Healthcare, Inc. for over ten years, where he led the growth, revitalization and diversification of the business that positioned Kindred as the largest provider of post-acute health care services in the United States. Most recently, Mr. Diaz was a Partner at Cressey & Company LP, a private equity firm focusing on healthcare services and HCIT companies. Mr. Diaz is an experienced director and operating executive, having served as an executive and board member of multiple public and private companies. He currently serves on the board of DaVita, Inc. (NYSE: DVA) and is a member of the Board of Trustees of Johns Hopkins Medicine. Mr. Diaz graduated from The American University with a B.S. in Business Administration and with a J.D. from The Georgetown University Law Center.
Heidrick & Struggles led the search process for Myriad.
About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to realizing the Companys full potential; officially introducing Paul during the Companys fourth quarter earnings call; advancing Myriads vision of being a trusted advisor transforming patients lives worldwide with pioneering molecular diagnostics; the Companys potential for innovation and growth; the Companys tremendous opportunity to transform its business, and strategically position itself for sustainable, profitable growth; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2020, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.
- 8: Techniques of Molecular Genetics - Biology LibreTexts - January 23rd, 2024
- Molecular Genetics and Metabolism Reports - ScienceDirect - December 18th, 2022
- Molecular Genetics and Metabolism | Journal - ScienceDirect - December 18th, 2022
- Molecular clock - Wikipedia - December 2nd, 2022
- Molecular Structure of Nucleic Acids: A Structure for Deoxyribose ... - December 2nd, 2022
- Molecular Genetics School of Graduate Studies - University of Toronto - October 13th, 2022
- Molecular pathways of major depressive disorder converge on the synapse | Molecular Psychiatry - Nature.com - October 13th, 2022
- Can artificial intelligence help identify best treatments for cancers? LSU researchers say yes - The Advocate - October 13th, 2022
- Results for the fiscal year on June 30, 2022 - Yahoo Finance - October 13th, 2022
- From the journals: MCP - ASBMB Today - October 13th, 2022
- From cave-dweller scientist to Nobel laureate - The Tribune India - October 13th, 2022
- Animal Genetics Market - Know the Revenue and Profit-Sources of the Industry - openPR - October 13th, 2022
- Molecular and Cell Biology and Genetics - Master of Science / PhD ... - September 25th, 2022
- What does the future hold for COVID-19? - UCLA Health Connect - September 25th, 2022
- Farooq Kperogi: Lies and truth about Obi, Atiku, and Tinubu - Peoples Gazette - September 25th, 2022
- Atavistik Bio Announces Formation of Scientific Advisory Board - Business Wire - September 25th, 2022
- Scientific Advances Point to Improved Understanding of Radiation Exposure - Livermore Independent - September 25th, 2022
- 19 million to investigate bold ideas in bioscience research - EurekAlert - September 25th, 2022
- Machel, Iwer among full list of National Awardees - Trinidad Guardian - September 25th, 2022
- Newly Discovered Protein Connected to Alzheimers Disease Risk - Neuroscience News - September 25th, 2022
- The Lab Report: Sharma Lab studies biodiversity of arachnids - The Badger Herald - September 16th, 2022
- Environmental Scientist Jesse Ausubel to Receive 2022 Nierenberg Prize for Science in the Public Interest - Scripps Institution of Oceanography - September 16th, 2022
- Malaria vax promising, to be cheap too - The Hans India - September 16th, 2022
- Dayton Therapeutics Discovers New Therapeutic Uses of Satraplatin for Treatment of Rare Lymphomas - StreetInsider.com - September 16th, 2022
- JNCASRs novel molecule prevents obesity in mice - The Hindu - September 16th, 2022
- Research Fellow in the Department of Medical and Molecular Genetics job with KINGS COLLEGE LONDON | 308234 - Times Higher Education - September 8th, 2022
- Seven Queen's researchers elected to the Royal Society of Canada - Queen's University - September 8th, 2022
- Molecular Biology with an Industrial Placement Year BSc - India Education Diary - September 8th, 2022
- Whole Exome Sequencing Market Projected to Reach CAGR of 19.0% Forecast by 2029, Global Trends, Size, Share, Growth, Future Scope and Key Player... - September 8th, 2022
- Molecular prevalence and genetic diversity of Bartonella spp. in stray cats of zmir, Turkey - Parasites & Vectors - Parasites & Vectors - August 30th, 2022
- How light and temperature work together to affect plant growth - EurekAlert - August 30th, 2022
- Ancient Mummies' Lousy View of the Past - The Scientist - August 30th, 2022
- 'Gray blanket' over Australia: Genetics may have aided European rabbit invasion of continent in 1859, says study - Down To Earth Magazine - August 30th, 2022
- Meet the UNC Pembroke professor leading research on Alzheimers disease - The Robesonian - August 30th, 2022
- Massive Genome Study Informs the Biology of Reading and Language - Neuroscience News - August 30th, 2022
- People in the News at Gencove, IsoPlexis, HTG Molecular, More - GenomeWeb - August 30th, 2022
- Professor (with Head of Department potential), Department of Medical & Molecular Genetics job with KINGS COLLEGE LONDON | 304203 - Times Higher... - August 14th, 2022
- Kathy C. Cordes, a former Baltimore Sun artist who later worked at NASA's Space Telescope Institute, dies Baltimore Sun - Baltimore Sun - August 14th, 2022
- Discovery of the interactions between plants and arbuscular mycorrhizal fungi - EurekAlert - August 14th, 2022
- A new drug could repair stroke damage to memory and movement - Freethink - August 14th, 2022
- CDC Says Recent Flu Season Mild, Maybe Owing to COVID Precautions - Medscape - August 14th, 2022
- Study Using NanoStrings GeoMx Digital Spatial Profiler Featured on the Cover of Nature Genetics - BioSpace - August 14th, 2022
- New virus detected in China; here's everything you need to know about it - WCCO - August 14th, 2022
- Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine... - August 14th, 2022
- Psychiatry, Fraud, and the Case for a Class-Action Lawsuit - Mad In America - Mad in America - August 14th, 2022
- Scientists Grow Mouse Embryos Without Sperm Or Eggs - EverythingGP - August 14th, 2022
- The Pitfalls of Evolutionary Genomics - SciTechDaily - August 14th, 2022
- How a simple home DNA test unravelled the genetic code that could help prolong my life - The National - August 14th, 2022
- Graduate Research Officer job with UNIVERSITY OF WESTERN AUSTRALIA | 304277 - Times Higher Education - August 14th, 2022
- These Are the Degrees of the Future - Gizmodo - August 14th, 2022
- University of Chicago obituaries - University of Chicago - August 14th, 2022
- Letter: Abortion and social planning - Daily Herald - August 14th, 2022
- Postdoctoral Researcher, Seaweed Molecular Biology, Physiology and Genetics, Ryan Institute, School job with NATIONAL UNIVERSITY OF IRELAND, GALWAY |... - August 5th, 2022
- Researchers crack 30-year-old mystery of odour switching in worms - University of Toronto - August 5th, 2022
- 1st synthetic mouse embryos complete with beating hearts and brains created with no sperm, eggs or womb - Livescience.com - August 5th, 2022
- Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors - Business Wire - August 5th, 2022
- Luke Goldman: Using eDNA to save the Atlantic cod - UMaine News - University of Maine - University of Maine - August 5th, 2022
- Duke Announces Winners of the 2022 DST Spark Seed Grants - Duke Today - July 27th, 2022
- WVXU: UC scientists are deep-freezing molecules. Here's why they're so excited about it - University of Cincinnati - July 27th, 2022
- Better Diagnosis and Treatment: Genetic Clues to Age-Related Macular Degeneration - SciTechDaily - July 27th, 2022
- Regeneron Announces the 2022 Winners of the Regeneron Prize for Creative Innovation - PR Newswire - July 27th, 2022
- Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA - GlobeNewswire - July 27th, 2022
- How is Biotechnology revolutionising food and beverage industry? - The Statesman - July 27th, 2022
- ACP offers guidance on the ethical use of genetic testing and precision medicine - EurekAlert - July 27th, 2022
- Barbour Appointed Dean of The Graduate School and Vice Provost for Graduate Education - Duke Today - July 19th, 2022
- UC scientists are deep-freezing molecules. Here's why they're so excited about it - WVXU - July 19th, 2022
- Research Fellow, Molecular Biology / Recombinant Protein Production and Purification (Biol Sci) job with NATIONAL UNIVERSITY OF SINGAPORE | 301436 -... - July 19th, 2022
- UF researchers discover new way to inhibit virus that causes COVID-19 - University of Florida - July 19th, 2022
- Streamlined Genomic Testing Platforms Are Taking on A Bigger Role in Cancer Care - OncLive - July 19th, 2022
- Bachelor of Science in Biology - National University - July 19th, 2022
- Genes may influence our successes and failures in life, according to Professor Kathryn Paige Harden - ABC News - July 19th, 2022
- Lecturer for Department of Experimental Biology job with MASARYK UNIVERSITY | 301048 - Times Higher Education - July 19th, 2022
- Lecturer in Biology (Education Focused) job with UNIVERSITY OF SYDNEY | 300815 - Times Higher Education - July 19th, 2022
- People's University Is All About Dinosaurs This Summer - Wheeling Intelligencer - July 19th, 2022
- Radiologists hope to use AI to improve readings - University of Miami: News@theU - July 19th, 2022
- Rare Disease Genetic Testing Market 2022 Emerging Trends, Comprehensive Study With Top Companies and Key Players till 2030 - Taiwan News - July 11th, 2022
- Proteases implicated in ulcerative colitis - ASBMB Today - July 11th, 2022
- Cancer has been a scourge for centuries, advances in science have made the disease far less intractable - The Indian Express - July 11th, 2022
- Scientists discover key genes behind insect migrations - EurekAlert - July 11th, 2022
- Neuroimaging Techniques and What a Brain Image Can Tell Us - Technology Networks - July 11th, 2022